Bolt Biotherapeutics Inc (BOLT)

$4.57 -0.13 (-2.77%)
Market Cap 9.02M
Revenue (ttm) 7.69M
Net Income (ttm) -63.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -820.81%
Debt to Equity Ratio 0.00
Volume 135,900
Avg Vol 31,432
Day's Range N/A - N/A
Shares Out 1.92M
Stochastic %K 13%
Beta 0.93
Analysts Sell
Price Target $6.50

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 665 9295
Address:
900 Chesapeake Drive, Redwood City, United States
skyrockets_Inc
skyrockets_Inc Nov. 14 at 4:35 PM
$BOLT If you aren't buying as much of this as you can, you are insane. This one is going to make a lot of people on this board rich. Perfect set up and a ticking time bomb before it rockets away. I'm in for 20k shares and adding more daily while it's this cheap.
1 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 13 at 5:26 PM
$BOLT "Under the Genmab Agreement, the Company is eligible to receive total potential milestone payments of up to $125.0 million in development milestones and $160.0 million in sale milestones per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties at rates from a single-digit to mid-teens percentage based on net sales of each therapeutic candidate" Big pharma Genmab and BOLT are jointly developing THREE candidates. Each w/ potential of up to 285mil in milestone payments......company is sitting at a ~10m market cap right now. Genmab $GMAB a 20B company. Would make sense for a takeover now rather than later......just sayin'
0 · Reply
Herrm
Herrm Nov. 13 at 3:21 PM
$BOLT
0 · Reply
MindfulMonkey
MindfulMonkey Nov. 13 at 2:57 PM
$BOLT bulls here aren't bulls for earnings, they're bulls for partnership catalysts. They're coming.
1 · Reply
SheriffGrover
SheriffGrover Nov. 13 at 2:06 PM
$BOLT Looking good Pre-Market ...
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 10:40 PM
$BOLT -Super low float of 1.92m shares. LOW FLOAT MANIA. -50%+ institutional and insider owned, including TANG Capital -$20/share in cash, $15/share in stockholder equity -Phase 1 trial BDC-4192 ongoing w/ asset that has already shown COMPLETE tumor regression in preclincal models. -Two other pre-clincal assets that have shown promise available for partnering -BDC-3042 completed Phase 1 trials in early 2025 and showed good results. Available for partnering. -Partnership with two big pharmas Genmab and Toray working on a total of 4 different assets , 3 w/ Genmab and 1 w/ Toray. This may the buyout candidates IMO. -Cash runway through 2027 w/ streamlined operations. Could you have a better description than the above? I don't think we are even going to make it to see BDC-4192 data in 3Q 2026, I think this will be bought out long before IMO. Too cheap and too much potential value. And with a 1.92m float and NO DILUTION risk there's always the chance of a low float mega run as well. LFG
0 · Reply
d_risk
d_risk Nov. 12 at 10:01 PM
$BOLT - Bolt Biotherapeutics, Inc. - 10Q - Updated Risk Factors BOLT adds a new risk: evolving U.S. and global healthcare reforms—including the ACA, Inflation Reduction Act, and OBBBA—could impact product pricing, reimbursement, and insurance coverage, potentially hurting business. #Biotechnology #InsuranceCoverage #ReimbursementRisk #PricingRisk #HealthcareReform 🟢 Added 🟠 Removed https://d-risk.ai/BOLT/10-Q/2025-11-12
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:14 PM
$BOLT "The data indicate that the claudin 18.2 ISAC stimulates a powerful, tumor-dependent immune response that culminates in complete tumor regression and the establishment of immunological memory. The ensuing T cell-dependent immunity was robust enough to prevent the growth of tumors lacking claudin 18.2 expression during rechallenge experiments. Furthermore, the ISAC demonstrated superior anti-tumor activity compared to both Topo1- and MMAE-based ADCs, particularly in a low-antigen model of claudin 18.2-expressing cancer. Taken together, these findings provide a strong rationale for the ongoing clinical development of BDC-4182." If this company isn't a takeover target, I don't what is. This drug above ^^^ in development and 3 others available for partnering.......and then on top of that 2 that are already partnered w/ big pharma Genmab and Toray. That partnership continues to progress. $20/share in cash enough into 2027 . Rockets fly soon!
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:12 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:10 PM
$BOLT Earnings are out. Making progress on all fronts. BDC-3142 still in Phase 1 and recently shared progress at November conference. 39m in cash w/ no debt equates to roughly $20/share in cash alone.
0 · Reply
Latest News on BOLT
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 2 days ago

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Oct 1, 2025, 4:05 PM EDT - 6 weeks ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:05 PM EDT - 3 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 6 months ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

May 8, 2025, 8:00 AM EDT - 6 months ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 7 months ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 24, 2025, 4:20 PM EDT - 8 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Feb 25, 2025, 4:05 PM EST - 9 months ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Feb 11, 2025, 4:05 PM EST - 9 months ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 4, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 2, 2024, 11:11 AM EDT - 1 year ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 31, 2024, 11:25 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 31, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 29, 2024, 8:49 PM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Aug 27, 2024, 11:00 AM EDT - 1 year ago

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 26, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Jul 19, 2024, 11:10 AM EDT - 1 year ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jul 3, 2024, 4:47 PM EDT - 1 year ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jun 24, 2024, 3:36 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:37 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

skyrockets_Inc
skyrockets_Inc Nov. 14 at 4:35 PM
$BOLT If you aren't buying as much of this as you can, you are insane. This one is going to make a lot of people on this board rich. Perfect set up and a ticking time bomb before it rockets away. I'm in for 20k shares and adding more daily while it's this cheap.
1 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 13 at 5:26 PM
$BOLT "Under the Genmab Agreement, the Company is eligible to receive total potential milestone payments of up to $125.0 million in development milestones and $160.0 million in sale milestones per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties at rates from a single-digit to mid-teens percentage based on net sales of each therapeutic candidate" Big pharma Genmab and BOLT are jointly developing THREE candidates. Each w/ potential of up to 285mil in milestone payments......company is sitting at a ~10m market cap right now. Genmab $GMAB a 20B company. Would make sense for a takeover now rather than later......just sayin'
0 · Reply
Herrm
Herrm Nov. 13 at 3:21 PM
$BOLT
0 · Reply
MindfulMonkey
MindfulMonkey Nov. 13 at 2:57 PM
$BOLT bulls here aren't bulls for earnings, they're bulls for partnership catalysts. They're coming.
1 · Reply
SheriffGrover
SheriffGrover Nov. 13 at 2:06 PM
$BOLT Looking good Pre-Market ...
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 10:40 PM
$BOLT -Super low float of 1.92m shares. LOW FLOAT MANIA. -50%+ institutional and insider owned, including TANG Capital -$20/share in cash, $15/share in stockholder equity -Phase 1 trial BDC-4192 ongoing w/ asset that has already shown COMPLETE tumor regression in preclincal models. -Two other pre-clincal assets that have shown promise available for partnering -BDC-3042 completed Phase 1 trials in early 2025 and showed good results. Available for partnering. -Partnership with two big pharmas Genmab and Toray working on a total of 4 different assets , 3 w/ Genmab and 1 w/ Toray. This may the buyout candidates IMO. -Cash runway through 2027 w/ streamlined operations. Could you have a better description than the above? I don't think we are even going to make it to see BDC-4192 data in 3Q 2026, I think this will be bought out long before IMO. Too cheap and too much potential value. And with a 1.92m float and NO DILUTION risk there's always the chance of a low float mega run as well. LFG
0 · Reply
d_risk
d_risk Nov. 12 at 10:01 PM
$BOLT - Bolt Biotherapeutics, Inc. - 10Q - Updated Risk Factors BOLT adds a new risk: evolving U.S. and global healthcare reforms—including the ACA, Inflation Reduction Act, and OBBBA—could impact product pricing, reimbursement, and insurance coverage, potentially hurting business. #Biotechnology #InsuranceCoverage #ReimbursementRisk #PricingRisk #HealthcareReform 🟢 Added 🟠 Removed https://d-risk.ai/BOLT/10-Q/2025-11-12
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:14 PM
$BOLT "The data indicate that the claudin 18.2 ISAC stimulates a powerful, tumor-dependent immune response that culminates in complete tumor regression and the establishment of immunological memory. The ensuing T cell-dependent immunity was robust enough to prevent the growth of tumors lacking claudin 18.2 expression during rechallenge experiments. Furthermore, the ISAC demonstrated superior anti-tumor activity compared to both Topo1- and MMAE-based ADCs, particularly in a low-antigen model of claudin 18.2-expressing cancer. Taken together, these findings provide a strong rationale for the ongoing clinical development of BDC-4182." If this company isn't a takeover target, I don't what is. This drug above ^^^ in development and 3 others available for partnering.......and then on top of that 2 that are already partnered w/ big pharma Genmab and Toray. That partnership continues to progress. $20/share in cash enough into 2027 . Rockets fly soon!
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:12 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 9:10 PM
$BOLT Earnings are out. Making progress on all fronts. BDC-3142 still in Phase 1 and recently shared progress at November conference. 39m in cash w/ no debt equates to roughly $20/share in cash alone.
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 11 at 4:06 PM
$BOLT All these new names posting in here now tells you something is about to happen.....
0 · Reply
Turkisaleh
Turkisaleh Nov. 10 at 11:15 PM
$BOLT what is target price for short term and long term?
2 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 10 at 8:22 PM
$BOLT $GLTO announced earnings on Thur and then today announced funding deal. Stock is up ~300% $BOLT is the next low float runner. With $15/share in cash, no debt, ~50% tutes holding including TANG. 1 asset in Phase 1 trial, 3 assets available for partnering , and two assets already partnered w/ big Pharam Genmab and Toray. This is the cleanest set up I've seen in a long time and is a easy takeover target IMO. Let's go!
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 10 at 8:09 PM
$BOLT over $15/share in cash
1 · Reply
Investor1337
Investor1337 Nov. 10 at 3:30 PM
$BOLT $GLTO $ORPH I was right on glto and orph --> next one is Bolt ;)
1 · Reply
SheriffGrover
SheriffGrover Nov. 9 at 1:52 PM
$BOLT wonder how much cash they have left…
1 · Reply
NoFearHere
NoFearHere Nov. 8 at 9:57 PM
$BOLT earnings coming should push it to 4.00 there horrible EPS WAY negative despite being worse the year prior still horrid.. read⤵️ unless some news changes course
0 · Reply
NoFearHere
NoFearHere Nov. 8 at 5:45 PM
$BOLT if fall contines 4.00 Trendline Stops it
0 · Reply
greko50
greko50 Nov. 8 at 3:44 PM
$BOLT Going to start a position again here after being out for quite sometime, as 8 mil mc is ridiculous cheap. If/when a partner is announced for BDC-3042, this should easily be a 3x from here if not more. Also, BDC-4182 was going to have a readout in 1H/2026 and is now pushed back to 3Q/2026 due to a modifying of the trial to allow for step-up dosing after observing a "strong immune response at initial dose levels". So a couple shots on goal at ridiculously cheap levels imo, just have to be patient and wait......
0 · Reply
neverhorizontal
neverhorizontal Nov. 8 at 2:20 PM
$BOLT 50% workforce reduction is not a good sign
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 7 at 8:49 PM
$BOLT officially trading less than 1/4 cash value. Very rare to see that ratio. This is the BOTTOM. Adding more here. 3k more shares .
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 7 at 4:20 PM
$BOLT Market in general is blood red today. Good day to buy more! I'm in for 2k more shares.
0 · Reply